Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1225120 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3HIF1AHSD17B10 | |
| SCHEMBL1225118 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3HIF1AHSD17B10 | |
| SCHEMBL1932043 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3HIF1AHSD17B10 | |
| SCHEMBL13510425 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3HIF1AHSD17B10 | |
| SCHEMBL31048385 | 0.98 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3HIF1AHSD17B10 | |
| SCHEMBL25446671 | 0.94 | — | — | |
| SCHEMBL3696352 | 0.94 | — | — | |
| SCHEMBL2647260 | 0.94 | — | — | |
| SCHEMBL5053538 | 0.94 | — | — | |
| SCHEMBL2646374 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569679-B2 | Treatment delivery system | WearOptimo Pty Ltd (AU) | 2026-03-10 | — | — | US | disclosed |
| US-12484814-B2 | Actuator system | WearOptimo Pty Ltd (AU) | 2025-12-02 | — | — | US | disclosed |
| US-20250025078-A1 | ELECTRODE ARRANGEMENT | WearOptimo Pty Ltd (AU) | 2025-01-23 | — | — | US | disclosed |
| US-20230053962-A1 | ANALYTE MEASUREMENT SYSTEM | WearOptimo Pty Ltd (AU) | 2023-02-23 | — | — | US | disclosed |
| US-20230035892-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | FLAGSHIP PIONEERING, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20220346679-A1 | ANALYTE MEASUREMENT SYSTEM | WearOptimo Pty Ltd (AU) | 2022-11-03 | — | — | US | disclosed |
| EP-4037552-A1 | ANALYTE MEASUREMENT SYSTEM | Wearoptimo Pty Ltd (AU) | 2022-08-10 | — | — | EP | disclosed |
| US-11274158-B2 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20220033490-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING CHRNA6 INHIBITORS | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2022-02-03 | — | — | US | disclosed |
| US-20210402182-A1 | TREATMENT DELIVERY SYSTEM | WearOptimo Pty Ltd (AU) | 2021-12-30 | — | — | US | disclosed |
| US-20190240293-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATING AN ANTI-CANCER IMMUNE RESPONSE | CYGNAL THERAPEUTICS, INC. | 2019-08-08 | — | — | US | disclosed |
| US-20190233527-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY OR AUTOIMMUNE DISEASES OR CONDITIONS USING CALCITONIN RECEPTOR ACTIVATORS | FLAGSHIP PIONEERING, INC. | 2019-08-01 | — | — | US | disclosed |
| CN-108391756-A | A kind of preparation and application of milking sow protein source additive | 中国热带农业科学院热带作物品种资源研究所 | 2018-08-14 | — | — | CN | disclosed |
| US-20180132516-A1 | POSITIVE ALLOSTERIC MODULATORS OF SWEET TASTE | SENSORYGEN INC (US) | 2018-05-17 | — | — | US | disclosed |
| CN-107156194-A | Environment-friendly high-efficiency citrus insecticide | 嘉禾天奉富硒果业有限公司 | 2017-09-15 | — | — | CN | disclosed |
| US-20150362482-A1 | METHODS OF DETECTING NEUROTOXIN USING SYNAPTIC ACTIVITY | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2015-12-17 | — | — | US | disclosed |
| US-20150153325-A1 | TOXIN DETECTION USING STEM CELL DERIVED NEURONS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2015-06-04 | — | — | US | disclosed |
| WO-2014138663-A1 | METHODS OF DETECTING NEUROTOXIN USING SYNAPTIC ACTIVITY | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE ARMY, on behalf of (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2013170206-A1 | TOXIN DETECTION USING STEM CELL DERIVED NEURONS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, ON BEHALF OF U.S. ARMY RESEARCH & MATERIAL COMMAND (US) | 2013-11-14 | — | — | WO | disclosed |
| WO-2010131058-A1 | PRODUCT FOR THE PROTECTION AGAINST HONEYBEE MITES, AND METHOD FOR THE PREPARATION OF THE ACTIVE SUBSTANCE | VON BARTHELDNE ABRI JUDIT (HU) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033490-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING CHRNA6 INHIBITORS | CHRNA6, CHRNA1, CHRNB1 | SLC6A2 189/4885SLC6A4 510/4885SLC6A3 509/4885 |
| US-12569679-B2 | Treatment delivery system | PIEZO1, DSG1, KRT18 | SLC6A2 345/4885SLC6A4 575/4885SLC6A3 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.